Johnson M A, Stevens L M, Patel M V. "Method for the Synthesis of Iridium, (2,4-pentanedionato-κO2,κO4)bis[2-(5-phenyl-2-oxazolyl-κN3)phenyl-κC]-, (OC-6-33)-" [P]. US Patent, US 10244050 B2, 2018-02-02.
Mueller T, Stevens L M, Davis P L. "A Process for Preparing High-Purity Iridium, (2,4-pentanedionato-κO2,κO4)bis[2-(5-phenyl-2-oxazolyl-κN3)phenyl-κC]-, (OC-6-33)-" [P]. US Patent, US 10129036 B2, 2024-02-05.
参考文献 Literature
Garcia M, Rodriguez P. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chromatographia, 2023, 1178, (1), 6966-6970.
Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Rapid Commun. Mass Spectrom., 2021, 2005, 7056-7081.
Wang L, Li J, Zhang H. "Identification and Structural Characterization of a Novel Degradation Product of Iridium, (2,4-pentanedionato-κO2,κO4)bis[2-(5-phenyl-2-oxazolyl-κN3)phenyl-κC]-, (OC-6-33)- Using HRMS and NMR". J. Pharm. Biomed. Anal., 2020, 1988, (1), 6946-6962.
Wang L, Li J, Zhang H. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Chemosphere, 2012, 2159, (3), 5259-5282.